Treatment of gastric carcinoids

Kidd M, Modlin IM, Mane SM, et al.: Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease. Ann Surg 2006, 243:273–280.

Oberndorfer S: Karzinoide tumoren des dunndarms [in German]. Frankf Z Pathol 1907, 1:237–240.

Godwin JD 2nd: Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975, 36:560–569.

Berge T, Linell F: Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand 1976, 84:322–330.

Hodgson N, Koniaris LG, Livingstone AS, Franceschi D: Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 2005, 19:1610–1612.

Chen D, Zhao CM, Lindstrom E, et al.: Rat stomach ECL cells up-date of biology and physiology. Gen Pharmacol 1999, 32:413–422.

Conlon JM, Deacon CF, Richter G, et al.: Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush. Scand J Gastroenterol 1987, 22:97–105.

Solcia E, Rinidi G, Silini E, et al.: Enterochromaffin-like (ECL) cells and their growths: relationship to gastrin, reduced acid secretion and gastritis. Baillieres Clin Gastroenterol 1993, 7:149–165.

Rindi G, Luinetti O, Cornaggia M, et al.: Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993, 104:994–1006.

Manela FD, Ren J, Gao J, et al.: Calcitonin gene-related peptide modulates acid mediated somatostatin and gastrin release from rat antrum. Gastroenterology 1995, 109:701–706.

Galligan CJ, Lawton GP, Tang LH, et al.: Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995, 90:338–352.

Solcia E, Bordi C, Creutzfeld W, et al.: Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1998, 41:185–200.

Bordi C, Yu JY, Baggi MT, et al.: Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases. Cancer 1991, 67:663–672.

Borch K, Renyall H, Liedberg G, et al.: Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scand J Gastroenterol 1986, 21:357–363.

Modlin IM, Lye KD, Kidd M: Carcinoid tumor of the stomach. Surg Oncol 2003, 12:153–172.

Rindi G, Bordi C, Rappel S, et al.: Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996, 20:168–172.

Schindl M, Kaserer K, Niederle B: Treatment of gastric neuroendocrine tumors-the necessity of a type-adapted treatment. Arch Surg 2001, 136:49–54.

Moesta KT, Schlag P: Proposal for a new carcinoid tumor staging system based on tumor tissue infiltration and primary metastasis: a prospective multicentre carcinoid tumor evaluation study. West German Surgical Oncologists’ Group. Eur J Surg Oncol 1990, 16:280–288.

Bordi C, D’Adda T, Azzoni C, Ferraro G: Pathogenesis of ECL cell tumors in humans. Yale J Biol Med 1998, 71:273–284.

Jensen RT: Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998, 243:477–488.

Maggard MA, O’Connell JB, Ko CY: Updated population-based review of carcinoid tumors. Ann Surg 2004, 240:117–122.

Bordi C: Endocrine tumors of the stomach. Pathol Res Pract 1995, 191:373–380.

Nobels FR, Kwekkeboom DJ, Coopmans W, et al.: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997, 82:2622–2628.

Bordi C, Azzoni C, Feraro G, et al.: Sampling strategies for analysis of enterochromaffin-like cell changes in Zollinger-Ellison syndrome. Am J Clin Pathol 2000, 114:419–425.

Giovannini M, Seitz JF, Thomas P, et al.: Endoscopic ultrasound examination using a curved-array transducer in benign and malignant diseases of the stomach. Results in 30 patients [in French]. Gastroenterol Clin Biol 1993, 17:26–32.

Lindstrom E, Hakanson R: Neurohormonal regulation of secretion from isolated rat stomach ECL cells: a critical reappraisal. Regul Pept 2001, 97:169–180.

Modlin IM, Kidd M, Latich I, et al.: Current status of gastrointestinal carcinoids. Gastroenterology 2005, 128:1717–1751.

Lebtahi R, Le Cloirec J, Houzard C, et al.: Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. J Nucl Med 2002, 43:889–895.

Gibril F, Reynolds JC, Lubensky IA, et al.: Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J Nucl Med 2000, 41:1646–1656.

Zuetenhorst JM, Hoefnageli CA, Boot H, et al.: Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002, 23:735–741.

Modlin IM, Lye KD, Kidd M: A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004, 99:23–32.

Rappel S, Altendorfhofmann A, Stolte M: Prognosis of gastric carcinoid tumors. Digestion 1995, 56:455–462.

Meko J, Norton J: Management of patients with Zollinger-Ellison syndrome. Ann Rev Med 1995, 46:395–411.

Modlin IM, Kidd M, Lye KD: Biology and management of gastric carcinoid tumors: a review. Eur J Surg 2002, 168:669–683.

Galligan CJ, Lawton GP, Tang LH, et al.: Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995, 90:338–352.

Ichikawa J, Tanabe S, Koizumi W, et al.: Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy 2003, 35:203–206.

Hirschowitz BI, Griffith J, Pellegrin D, et al.: Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992, 102:1409–1418.

Modlin IM, Latich I, Kidd M, et al.: Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006, 4:526–547.

Welin SV, Janson ET, Sundin A, et al.: High-dose treatment with a long acting somatostatin analogue in patients with disseminated mid-gut carcinoid tumors. Eur J Endocrinol 2004, 151:107–112.

Arnold R, Trautmann ME, Creutzfeld W, et al.: Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Gut 1996, 172:61–67.

Dirix LY, Vermeulen PB, Fierens H, et al.: Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors—an antiangiogenic effect? Anticancer Drugs 1996, 7:175–181.

Schally A: Oncological applications of somatostatin analogue. Cancer Res 1988, 48:6977–6985.

Hillman N, Herranz L, Alverez C, et al.: Efficacy of octreotide in the regression of a metastatic carcinoid tumor despite negative imaging with In-111-pentetreotide (Octreoscan). Exp Clin Endocrinol Diabetes 1998, 106:226–230.

Kvols LK, Moertel CG, O’Connell MJ, et al.: Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986, 315:663–666.

Oberg K: Treatment of neuroendocrine tumors. Cancer Treat Rev 1994, 20:331–355.

Oberg K: Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology 2004, 80(Suppl 1):57–61.

Frolich JC, Bloomgarden ZT, Oates JA, et al.: The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 1978, 299:1055–1057.

Dharmsathaphorn K, Sherwin RS, Cataland S, et al.: Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Intern Med 1980, 92:68–69.

Schnirer II, Yao JC, Ajani JA: Carcinoid—a comprehensive review. Acta Oncol 2003, 42:672–692.

Ahlman H, Kolby L, Lundell, et al.: Clinical management of gastric carcinoid tumors. Digestion 1994, 55Suppl 3):77–85.

Higam AD, Dimaline R, Varro A, et al.: Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Gastroenterology 1998, 114:817–822.

Dakin GF, Warner RR, Pomp A, et al.: Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol 2006, 93:368–372.

Comaru-Schally AM, Schally AV: A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs (review). Int J Oncol 2005, 26:301–309.

Kaltsas G, Rockall A, Papadogias D, et al.: Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumors. Eur J Endocrinol 2004, 151:15–27.

Krenning EP, Kwekkeboom DJ, Valkema R, et al.: Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004, 1014:234–245.

Boerlin V, van der Hoek J, Beglinger Ch, et al.: New insights on SOM230, a universal somatostatin receptor ligand. J Endocrinol Invest 2003, 26(8 Suppl):14–16.

Bruns C, Lewis I, Briner U, et al.: SOM230: a novel somatostatin peptidomimetic with broad somatostatin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002, 146:707–716.

Schmid HA, Schoeffter P: Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004, 80(Suppl 1):47–50.

Kvols L, Oberg K, de Herder W: Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR [abstract]. Proc Am Soc Clin Oncol 2005, 23:8024.

Yao JC, Chamsangavej C, Faria SC: Rapid decrease in blood flow (BF), blood volume (BV), and vascular permeability (PS) in carcinoid patients treated with bevacizumab. ASCO annual meeting proceedings (post-meeting edition) [abstract]. J Clin Oncol 2004, 22:3013.

Carr K, Yao JC, Rashid A: A phase II trial of imatinib in patients with advanced carcinoid tumor. ASCO annual meeting proceedings (post-meeting edition) [abstract]. J Clin Oncol 2004, 22:4124.